Revenue: As of FY2026 Q3, the actual value is USD 0.

EPS: As of FY2026 Q3, the actual value is USD -0.24.

EBIT: As of FY2026 Q3, the actual value is USD -15.18 M.

Financial Highlights (Three Months Ended March 31, 2026 vs. 2025)

Total Expenses

Benitec Biopharma Inc.’s total expenses for the three months ended March 31, 2026, were $13,582 thousand, a decrease from $15,335 thousand for the same period in 2025.

Research and Development Expenses

Research and development expenses for Benitec Biopharma Inc. were $6,298 thousand for the three months ended March 31, 2026, compared to $6,495 thousand for the three months ended March 31, 2025.

General and Administrative Expenses

General and administrative expenses for Benitec Biopharma Inc. decreased to $7,284 thousand for the three months ended March 31, 2026, from $8,840 thousand in the prior year’s comparable period.

Loss from Operations

The loss from operations for Benitec Biopharma Inc. for the three months ended March 31, 2026, was -$13,582 thousand, an improvement from a loss of -$15,335 thousand for the three months ended March 31, 2025.

Net Loss Attributable to Shareholders

Net loss attributable to shareholders for Benitec Biopharma Inc. for the three months ended March 31, 2026, was -$11,935 thousand, compared to -$14,501 thousand for the three months ended March 31, 2025.

Financial Highlights (Nine Months Ended March 31, 2026 vs. 2025)

Net Loss Attributable to Shareholders

For the nine months ended March 31, 2026, Benitec Biopharma Inc.’s net loss attributable to shareholders was -$32,737 thousand, compared to -$29,112 thousand for the nine months ended March 31, 2025.

Cash Position

Cash and Cash Equivalents

As of March 31, 2026, Benitec Biopharma Inc. reported cash and cash equivalents of $184,761 thousand.

Operational Update and Outlook

Benitec Biopharma Inc. anticipates updated interim clinical study results for its BB-301 program’s Cohort 1 and Cohort 2 patients in the second half of 2026. The company plans to engage with the U.S. Food and Drug Administration (FDA) mid-year to finalize the BB-301 pivotal study design. Benitec Biopharma Inc. is well-capitalized to fund the BB-301 program through the completion of its pivotal study.